<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456570</url>
  </required_header>
  <id_info>
    <org_study_id>Progestins and ovarian cyst</org_study_id>
    <nct_id>NCT03456570</nct_id>
  </id_info>
  <brief_title>The Efficacy of Progestins in Treatment of Functional Ovarian Cyst</brief_title>
  <official_title>The Efficacy of Progestins in Treatment of Functional Ovarian Cyst</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether the use of progesterone only pills has a
      beneficial effect over the expectant management of functional ovarian cyst or not , through a
      sample of female patients within the reproductive years
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An ovarian cyst is a common gynecological problem and is divided into 2 main categories;
      physiological and pathological In relative frequency, functional cysts account for about 24%
      of all ovarian cysts, benign cysts 70% and malignant 6% Functional cysts are the most common
      masses seen in the premenopausal ovary and are estimated to affect 8%-20% of
      reproductive-aged women

      Pain or discomfort in the lower abdomen Severe pain from torsion (twisting) or rupture - Cyst
      rupture is characterized by sudden, sharp, unilateral pelvic pain; this can be associated
      with trauma, exercise, or coitus. Cyst rupture can lead to peritoneal signs, abdominal
      distention, and bleeding (which is usually self-limited) Discomfort with intercourse,
      particularly deep penetration Changes in bowel movements such as constipation Pelvic pressure
      causing tenesmus or urinary frequency Menstrual irregularities Precocious puberty and early
      menarche in young children Abdominal fullness and bloating Indigestion, heartburn, or early
      satiety Hyperpyrexia - This may result from some complications of ovarian cysts, such as
      ovarian torsion Adnexal or cervical motion tenderness In current clinical practice ,
      gynecologists treat functional ovarian cysts with either oral Contraceptive pills or
      expectant management alone. we presume using progesterone only pills for treatment of
      functional ovarian cyst
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disappearance of cyst</measure>
    <time_frame>2 months</time_frame>
    <description>ultrasound evaluation
Post-menstrual or delayed menses for 1 week after treatment Patients will be asked about residual symptoms Then TVUS if
resolved , another examination will be scheduled after 1 month post-menstrual
decreasing in size , another course of treatment will be offered
stationary or increasing ,patient will be offered COCs (0.15 mg levonorgestrel and 0.03 mg ethinyl estradiol)
complicated ( torsion or rupture ) , patient will be subjected to surgery</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Functional Ovarian Cyst</condition>
  <condition>Progesterone</condition>
  <arm_group>
    <arm_group_label>progesterone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>these patients will be offered Dydrogesterone 10 mg twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>those patients will be offered placebo tablets twice daily will be offered for 10 days , then they will be seen Post-menstrual or delayed menses for 1 week after treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dydrogesterone 10 mg</intervention_name>
    <description>Dydrogesterone 10 mg twice daily</description>
    <arm_group_label>progesterone</arm_group_label>
    <other_name>duphaston 10 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>oral tablets twice daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients at reproductive age (18-44) Menstruating ovarian cyst (a cyst 3-10 cm
             in diameter, unilateral , unilocular ,clear content) BMI : patients with normal BMI
             (18.5-24.9) and overweight (25-29.9) included

        Exclusion Criteria:

          -  Exclusion criteria are ovarian payhology (dermoid, endometriosis or malignancies)

        Complicated cyst (rupture, torsion) Patients receiving hormonal treatment for the previous
        3 cycles History of surgical removal of ovarian cyst Comorbidities like uncontrolled DM
        ,hypertension and tuberculosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>amgad saber, bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>amgad saber, bachelor</last_name>
    <phone>002 01226082579</phone>
    <email>amgadmagdy59@yahoo.com</email>
  </overall_contact>
  <reference>
    <citation>Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. Cochrane Database Syst Rev. 2014 Apr 29;(4):CD006134. doi: 10.1002/14651858.CD006134.pub5. Review.</citation>
    <PMID>24782304</PMID>
  </reference>
  <reference>
    <citation>Goh W, Bohrer J, Zalud I. Management of the adnexal mass in pregnancy. Curr Opin Obstet Gynecol. 2014 Apr;26(2):49-53. doi: 10.1097/GCO.0000000000000048. Review.</citation>
    <PMID>24614018</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>amgad magdy saber</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progestins</mesh_term>
    <mesh_term>Dydrogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

